Director Investor Relations 45 33 44 77 30Cell 45 25 27 47

This valuable resource providesthe freedom and convenience to conduct further research into the company at yourwill, be it data-mining or integration into forecast models. Report Summary This 91-page research report provides an unparalleled breadth anddiversity of information on Deluxe Corporation and its relevant industry. The summary of the company's operationsand structure, backed up by crucial financial numbers, allows one to quicklyunderstand the company. And the inclusion of hard-to-find data such as sales bysegment, patent activities, subsidiary listings, and executive compensationfurther enhance this research. The industry data, with a macroeconomic perspective, provides the indispensablecontext of the arena in which the company operates. In the cost analysissection, 67 upstream industries are analyzed to offer insight into the supplychain cost structure. For the channel and pricing structure, 184 downstreamindustries are analyzed.

The competitive landscape section provides the numberof companies and their revenue share within the industry, the marketconcentration, and a list of major players. All related trade associations,industry standards, and trade publications are also listed. As kids (and maybe some adults, I'm not trying to crush any dreams here) eagerly await the gifts provided by a jolly fat guy in a red-and-white suit, I thought of another group of guys in red and white who could make my Christmas especially joyous.From Dec 14 to Dec. 25, I will mimic the pattern of the "12 Days of Christmas" song by asking for one thing on the first day, two things on the next day, and so on until Christmas.But, as this is the season of giving, I'd love for all of you to give me your thoughts on what you'd like from the Red Wings for Christmas, so please, post away!If you've been following along the past few days, you might notice that much of what I've asked for, is simply what Detroit has had before.The Red Wings have endured loss after loss, in the form of games and players. Neither can be sustained much longer if the Red Wings are to enter 2010 as a potential playoff team.The largest loss of late has been Henrik Zetterberg, who sustained aseparated shoulder on Dec. 3, if I get my eleven-day wish, would be Zetterberg's return date.This would be ideal, as the earliest game action he'd see would be Tuesday, Jan.

5 in Anaheim.This would give him two days of practice with the team before he'll be counted on, once again, to put the team on his back, in what is sure to be a tough game against the Ducks.While it is true that the Wings can ill-afford to be without any of the players currently on the IR, the Wings need Henrik Zetterberg the way humans need oxygen.The Wings are dying without him....10 ferocious minutes of play in the first period, nine Red Wings resting (during the Olympics), eight seed position in the West, seven points for Ville Leino, six straight games without an injury, five players clicking on the power play, four wins in a row, three solid periods of hockey every game, two defensemen scoring, and a dominating performance by Pavel Datsyuk! . 5, 2009 (GLOBE NEWSWIRE) Genmab A/S (OMX:GEN)announced today that the interim survival analysis of the Phase III pivotalstudy investigating zalutumumab (HuMax-EGFr(R)) in refractory head and neckcancer patients did not fulfill a criterion for early stopping after half thetrial has been completed.An Independent Data Monitoring Committee (IDMC) has evaluated the interimresultsand concluded that the benefit-risk profile of zalutumumab isacceptable. TheIDMC recommended that the trial should continue to enroll up to a maximum of 273patients and a final analysis performed.As of today, 212 patients have been randomized and the final analysis will takeplace once 231 deaths have occurred."We are pleased that this study will continue and are optimistic that the fullstudy results will show extended survival in patients with advanced head andneck cancer," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.About the trialThe pivotal study will include a maximum of 273 patients with squamouscellcarcinoma of the head and neck (SCCHN) who are refractory to or intolerantof standard platinum-based chemotherapy. Patients in the study will berandomized into two treatment groups: zalutumumab in combination with bestsupportive care or best supportive care alone. Patients treated with zalutumumabin combination with best supportive care will receive an initial dose of 8mg/kgof zalutumumab, followed by weekly infusions of a maintenance dose until diseaseprogression.The maintenance dose will be adjusted as necessary until the patient develops adose limiting skin rash, up to a maximum dose of 16 mg/kg of zalutumumab.Disease status will be assessed every 8 weeks by CT scan or MRI according toRECIST criteria until disease progression and patients will be followed forsurvival.The objective of the study is to evaluate the efficacy of zalutumumabincombination with best supportive care as compared to best supportive carealone in terms of overall survival. The primary endpoint in the study is overallsurvival from randomization until death.Conference CallGenmab will hold a conference call to discuss these results today, January 5,2009 at: 6:00 pm CET 5:00 pm GMT 12:00 pm ESTThe conference call will be held in English.The dial in numbers are as follows:1 877-856-1969 (in the US) and ask for the Genmab conference call1 719-325-4814 (outside the US) and ask for the Genmab conference callTo listen to a live webcast of the call please visit Genmab A/SGenmab is a leading international biotechnology company focused on developingfully human antibody therapeutics for the potential treatment of cancer.Genmab's world class discovery, development and manufacturing teams are usingcutting-edge technology to create and develop products to address unmet medicalneeds.

Our primary goal is to improve the lives of patients who are in urgentneed of new treatment options. For more information on Genmab's products andtechnology, visit press release contains forward looking statements. Actual results or performance may differ materiallyfrom any future results or performance expressed or implied by such statements.The important factors that could cause our actual results or performancetodiffer materially include, among others, risks associated with productdiscovery and development, uncertainties related to the outcome and conduct ofclinical trials including unforeseen safety issues, uncertainties related toproduct manufacturing, the lack of market acceptance of our products, ourinability to manage growth, the competitive environment in relation to ourbusiness area and markets, our inability to attract and retain suitablyqualified personnel, the unenforceability or lack of protection of our patentsand proprietary rights, our relationships with affiliated entities, changes anddevelopments in technology which may render our products obsolete, and otherfactors. For a further discussion of these risks, please refer to the section"Risk Management" in Genmab's Annual Report, which is available on Genmab does not undertake any obligation to update or reviseforward looking statements in this press release nor to confirm such statementsin relation to actual results, unless required by law.Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)and UniBody(R) are all trademarks of Genmab A/S.-0-CONTACT:Genmab A/SHelle Husted, Sr. Director, Investor Relations 45 33 44 77 30Cell: 45 25 27 47 .